acyclovir and Polyomavirus-Infections

acyclovir has been researched along with Polyomavirus-Infections* in 2 studies

Other Studies

2 other study(ies) available for acyclovir and Polyomavirus-Infections

ArticleYear
Biopsy-Proven BK Virus-Associated Nephropathy: Clinico-Pathologic Correlations.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2017, Volume: 15, Issue:3

    Our objective was to study the clinico-pathologic correlations in BK virus nephropathy.. We conducted a retrospective study of all patients with biopsy-proven polyoma (BK) virus infection. We compared their survival and renal outcomes versus BK virus-negative patients with biopsy-proven graft rejection. Histopathologic characterization by a blinded nephropathologist was performed.. BK nephropathy was found in 10 patients biopsied for graft dysfunction. All virus-positive patients received antithymocyte globulin induction therapy compared with only 59.3% of the BK-negative group (P = .06). The percentage of patients in the BK-negative group who received acyclovir was significantly higher than that in the BK-positive group (P = .01). After a mean observation period of 6.8 ± 3.2 years, 70% of the BK group had functioning grafts compared with 68% in the BK-negative group (P = .9) with similar 3-year graft survival in the 2 groups (80% and 90%; P = .8). Within the BK group, graft survival was better in the older group (P = .005) and in those with deceased donor kidney grafts (P = .016). Patients in the BK-negative group were heavier (mean weight of 64.3 ± 12.1 vs 46.7 ± 20.6 kg; P = .003). None of the histopathologic features studied had any effect on renal prognosis.. The risk factors for developing BK nephropathy were use of antithymocyte globulin, lower weight, and not using acyclovir as early prophylaxis. Within the BK nephropathy group, better graft survival was observed in deceased donor kidney recipients and in older patients. The viral load and polyoma virus nephropathy stage did not affect graft survival in this small sample study.

    Topics: Acyclovir; Adolescent; Adult; Antilymphocyte Serum; Antiviral Agents; Biopsy; BK Virus; Body Weight; Child; Female; Graft Survival; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Kidney; Kidney Transplantation; Male; Middle Aged; Polyomavirus Infections; Predictive Value of Tests; Retrospective Studies; Risk Factors; Saudi Arabia; Time Factors; Treatment Outcome; Tumor Virus Infections; Young Adult

2017
Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2007, Volume: 9, Issue:2

    A hematopoietic stem cell transplant recipient developed a mucosal herpes simplex virus-1 (HSV-1) infection while under acyclovir (ACV) treatment (HSV was later shown to be resistant to ACV). Concomitantly, the patient presented a hemorrhagic cystitis (HC) due to polyomavirus BK, for which intravenous cidofovir (CDV) was prescribed. The patient benefited from the broad-spectrum anti-DNA virus activity of CDV, and not only the HC resolved without signs of nephrotoxicity but also the HSV-1 lesions disappeared. This is the first report describing the effect of CDV on 2 simultaneous and unrelated DNA viral infections in an immunosuppressed transplant recipient. In addition, we describe here that this HSV-1 isolate possesses a unique phenotype and genotype.

    Topics: Acyclovir; Adolescent; Antiviral Agents; BK Virus; Bone Marrow Transplantation; Cidofovir; Cytosine; Drug Resistance, Viral; Female; Herpes Simplex; Herpesvirus 1, Human; Humans; Organophosphonates; Polyomavirus Infections; Tumor Virus Infections

2007